Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB.
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether combination chemotherapy is more effective with or without bevacizumab in treating metastatic colorectal cancer.

PURPOSE: This randomized phase III trial is studying second-line combination chemotherapy to see how well it works compared with or without bevacizumab in treating patients with metastatic colorectal cancer who have received first-line chemotherapy and bevacizumab.


Options:
A: Arm Label: Placebo/FOLFIRI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Arm Label: Aflibercept/FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Aflibercept/FOLFIRI
B: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: FOLFIRI | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386, Drug: FOLFIRI | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: FOLFIRI; Assigned to Arm(s): 1, 2
C: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluorouracil, Drug: irinotecan hydrochloride, Drug: leucovorin calcium, Drug: oxaliplatin | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: fluorouracil, Drug: irinotecan hydrochloride, Drug: leucovorin calcium, Drug: oxaliplatin | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: irinotecan hydrochloride; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): Arm I, Arm II
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Arm A, Arm B

Answer: C